Filtered By:
Source: International Journal of Stroke
Condition: Bleeding
This page shows you your search results in order of date.
Order by Relevance | Date
Total 20 results found since Jan 2013.
Is acute reperfusion therapy safe in acute ischemic stroke patients who harbor unruptured intracranial aneurysm?
ConclusionOur findings suggest that neither intravenous thrombolysis nor combination of intravenous and intra‐arterial thrombolysis increases the risk of aneurysmal hemorrhage in acute ischemic stroke patients who harbor unruptured intracranial aneurysms less than 10 mm in diameter. Their listing in exclusion criteria for intravenous thrombolysis should be reconsidered to assure appropriate use of acute reperfusion therapy in this group of patients.
Source: International Journal of Stroke - September 17, 2015 Category: Neurology Authors: Ashkan Mowla, Karanbir Singh, Sandhya Mehla, Mohammad K. Ahmed, Peyman Shirani, Haris Kamal, Chandan Krishna, Robert N. Sawyer, Marilou Ching, Adnan H. Siddiqui, Elad I. Levy, Kenneth V. Snyder, Annemarie Crumlish, L. N. Hopkins Tags: Research Source Type: research
Individual patient data meta‐analysis of antiplatelet regimens after noncardioembolic stroke or TIA: rationale and design
ConclusionsThis paper outlines inclusion criteria, outcome measures, baseline characteristics, and planned statistical analysis.
Source: International Journal of Stroke - August 18, 2015 Category: Neurology Authors: Jacoba P. Greving, Hans‐Christoph Diener, László Csiba, Werner Hacke, L. Jaap Kappelle, Peter J. Koudstaal, Didier Leys, Jean‐Louis Mas, Ralph L. Sacco, Juhani Sivenius, Ale Algra, Tags: Protocol Source Type: research
Safety and efficacy of intensive vs. guideline antiplatelet therapy in high‐risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388)
DiscussionThe trial has recruited more than 50% of its target sample size (latest number: 2399) and is running in 104 sites in 4 countries. One‐third of patients presented with a transient ischemic attack.
Source: International Journal of Stroke - June 16, 2015 Category: Neurology Tags: Protocol Source Type: research
TALOS: a multicenter, randomized, double‐blind, placebo‐controlled trial to test the effects of citalopram in patients with acute stroke
DiscussionSSRI treatment is well tolerated and overall beneficial in the wake of stroke; it may also be neuroprotective and prevent new vascular events.
Source: International Journal of Stroke - April 8, 2015 Category: Neurology Authors: Kristian Lundsgaard Kraglund, Janne Kaergaard Mortensen, Erik Lerkevang Grove, Søren Paaske Johnsen, Grethe Andersen Tags: Protocol Source Type: research
Cilostazol research in Asia: can it be applied to European and American patients?
Cilostazol is an antiplatelet drug often used in Asian countries like Korea, Japan, and China. However, it is rarely used in the west. Cilostazol inhibits phosphodiesterase, increases cyclic AMP concentrations, and consequently inhibits platelet aggregation. Interestingly, it also has vasodilatory activity, inhibits vascular smooth muscle proliferation, and protects the endothelium. Studies in Asia have shown that cilostazol is effective in the secondary prevention of stroke. Moreover, it is significantly less likely to cause bleeding complications than aspirin. Additional trials have shown that cilostazol is effective in ...
Source: International Journal of Stroke - March 4, 2015 Category: Neurology Authors: Jong S. Kim, Sun U. Kwon, Shinichiro Uchiyama Tags: Leading Opinion (Invited) Source Type: research
Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions
Small vessel disease encompasses lacunar stroke, white matter hyperintensities, lacunes and microbleeds. It causes a quarter of all ischemic strokes, is the commonest cause of vascular dementia, and the cause is incompletely understood. Vascular prophylaxis, as appropriate for large artery disease and cardioembolism, includes antithrombotics, and blood pressure and lipid lowering; however, these strategies may not be effective for small vessel disease, or are already used routinely so precluding further detailed study. Further, intensive antiplatelet therapy is known to be hazardous in small vessel disease through enhanced...
Source: International Journal of Stroke - February 1, 2015 Category: Neurology Authors: Philip M. Bath, Joanna M. Wardlaw Tags: Review Source Type: research
Statistical analysis plan for the ‘Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke’ (TARDIS) trial
DiscussionThis paper and attachment describe the trial's statistical analysis plan, as developed from the protocol during recruitment and prior to unblinding of data. The statistical analysis plan contains design and methods for analyses, and unpopulated tables and figures for the primary and baseline publications. The data from the trial will provide the first large‐scale randomized evidence for the use of intensive antiplatelet therapy for preventing recurrence after acute stroke and transient ischemic attack.
Source: International Journal of Stroke - December 31, 2014 Category: Neurology Authors: Philip M. W. Bath, Katie Robson, Lisa J. Woodhouse, Nikola Sprigg, Robert Dineen, Stuart Pocock, Tags: Protocol Source Type: research
Endovascular treatment for Small Core and Anterior circulation Proximal occlusion with Emphasis on minimizing CT to recanalization times (ESCAPE) trial: methodology
ESCAPE is a prospective, multicenter, randomized clinical trial that will enroll subjects with the following main inclusion criteria: less than 12 h from symptom onset, age > 18, baseline NIHSS >5, ASPECTS score of >5 and CTA evidence of carotid T/L or M1 segment MCA occlusion, and at least moderate collaterals by CTA. The trial will determine if endovascular treatment will result in higher rates of favorable outcome compared with standard medical therapy alone. Patient populations that are eligible include those receiving IV tPA, tPA ineligible and unwitnessed onset or wake up strokes with 12 h of last se...
Source: International Journal of Stroke - December 25, 2014 Category: Neurology Authors: Andrew M. Demchuk, Mayank Goyal, Bijoy K. Menon, Muneer Eesa, Karla J. Ryckborst, Noreen Kamal, Shivanand Patil, Sachin Mishra, Mohammed Almekhlafi, Privia A. Randhawa, Daniel Roy, Robert Willinsky, Walter Montanera, Frank L. Silver, Ashfaq Shuaib, Jeremy Tags: Protocol Source Type: research
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open‐label, parallel‐group trial
DiscussionThe CSPS.com is expected to provide evidence indicating whether secondary IS prevention in high‐risk patients can be improved by using DAPT involving cilostazol.
Source: International Journal of Stroke - December 8, 2014 Category: Neurology Authors: Kazunori Toyoda, Shinichiro Uchiyama, Haruhiko Hoshino, Kazumi Kimura, Hideki Origasa, Hiroaki Naritomi, Kazuo Minematsu, Takenori Yamaguchi, Tags: Protocols Source Type: research
The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double‐blind, placebo‐controlled multicenter trial
ConclusionThe SPAD trial is the first study to evaluate the safety and efficacy of dual antiplatelet agents, aspirin plus cilostazol, in comparison with aspirin alone in patients with both ischemic stroke or TIA and PAD. Results from this trial will provide important information on the merit of adding cilostazol to aspirin for slowing down progression of atherosclerosis in patients with ischemic stroke and PAD.
Source: International Journal of Stroke - November 14, 2014 Category: Neurology Authors: Jiann‐Shing Jeng, Yu Sun, Jiunn‐Tay Lee, Ruey‐Tay Lin, Chih‐Hung Chen, Helen L. Po, Huey‐Juan Lin, Chung‐Hsiang Liu, Ming‐Hui Sun, Mu‐Chien Sun, Chang‐Ming Chern, Li‐Ming Lien, Hou‐Chang Chiu, Han‐Hwa Hu, Hung‐Yi Chiou, Sien‐Ts Tags: Protocols Source Type: research
Rationale and design of Triple AXEL: trial for early anticoagulation in acute ischemic stroke patients with nonvalvular atrial fibrillation
DiscussionThe results of this proof‐of‐concept trial will guide go/no‐go decision to a large phase 3 confirmatory trial.
Source: International Journal of Stroke - October 26, 2014 Category: Neurology Authors: Keun‐Sik Hong, Yun Jung Choi, Sun U. Kwon, Tags: Protocols Source Type: research
Cerebral small vessel disease may be related to antiplatelet‐induced gastrointestinal bleeding
Source: International Journal of Stroke - September 18, 2014 Category: Neurology Authors: Sang Mi Noh, Bum Joon Kim, Jong S. Kim Tags: Letter to the editor Source Type: research
THrombolysis for Acute Wake‐up and unclear‐onset Strokes with alteplase at 0·6 mg/kg (THAWS) Trial
DiscussionThis trial may help determine if low‐dose alteplase at 0·6 mg/kg should be recommended as a routine clinical strategy for ischemic stroke patients with unclear‐onset time.
Source: International Journal of Stroke - August 4, 2014 Category: Neurology Authors: Masatoshi Koga, Kazunori Toyoda, Kazumi Kimura, Haruko Yamamoto, Makoto Sasaki, Toshimitsu Hamasaki, Takanari Kitazono, Junya Aoki, Kenta Seki, Kazunari Homma, Shoichiro Sato, Kazuo Minematsu, Tags: Protocols Source Type: research
Effectiveness and safety of antiplatelet in stroke patients with end‐stage renal disease undergoing dialysis
ConclusionsAntiplatelet therapy, especially aspirin, still offers safe and effective treatment for ischemic stroke prevention in patients with end‐stage renal disease undergoing dialysis.
Source: International Journal of Stroke - February 1, 2014 Category: Neurology Authors: Chung‐Yu Chen, Kun‐Tai Lee, Charles Tzu‐Chi Lee, Wen‐Ter Lai, Yaw‐Bin Huang Tags: Research Source Type: research
Endovascular therapeutic hypothermia for acute ischemic stroke: ICTuS 2/3 protocol
Therapeutic hypothermia improves neurological outcome after out‐of‐hospital cardiac arrest or neonatal hypoxic–ischemic injury. Although supported by preclinical evidence, therapeutic hypothermia for acute stroke remains under study. In the Intravascular Cooling in the Treatment of Stroke (ICTuS) trial, awake stroke patients were successfully cooled using an endovascular cooling catheter and a novel antishivering regimen. In the ICTuS‐L study, the combination of endovascular hypothermia and thrombolysis proved feasible; while hypothermia was associated with no increased risk of bleeding complications, there was an ...
Source: International Journal of Stroke - November 10, 2013 Category: Neurology Authors: Patrick D. Lyden, Thomas M. Hemmen, James Grotta, Karen Rapp, Rema Raman Tags: Protocols Source Type: research
